Dexcom (DXCM)Officer sold ~$117K

~$117K

Approx. value · 1,466 sh @ $80.00

105K

Holds after · shares reported

Traded

Sep 4, 2025

Filed

Sep 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 15, 2025Insider · 2 peopleInsiders: 3 sales (~$277K)
2. Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM Android App Model/Catalog Number: SW12299 Software Version: version 2.8.…
3. Jul 24, 2025FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ Android CGM App Model/Catalog Number: SW14245 Software Version: versions…
4. Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM watchOS App Model/Catalog Number: SW13355 Software Version: versions 2.8…
5. Jul 24, 2025FDARecall: Brand Name: Dexcom ONE+ Continuous Glucose Monitoring System Product Name: Dexcom ONE+ iOS CGM App Model/Catalog Number: SW14244 Software Version: versions 1.4…
6. Jul 24, 2025FDARecall: Brand Name: Dexcom G7 Continuous Glucose Monitoring System Product Name: Dexcom G7 CGM iOS App Model/Catalog Number: SW12300 Software Version: version 2.8.0 an…
7. Jul 28, 2025InsiderOfficer sold ~$130K of DXCM shares in the open market
8. Aug 15, 2025Insider · 2 peopleInsiders: 3 sales (~$263K)
9. Aug 27, 2025Layoff notice · 6290-6350 Sequence Drive San Diego CA 92121Layoff notice filed in CA: 319 employees
10. Aug 28, 2025FDARecall: Brand Name: Dexcom G6 Continuous Glucose Monitoring System Product Name: Dexcom G6 and G6 Pro Android US CGM App Model/Catalog Number: SW11678 Software Version…
11. Sep 2, 2025InsiderOfficer sold ~$358K of DXCM shares in the open market
12. Sep 4, 2025 · this disclosureInsiderOfficer sold ~$117K of DXCM shares in the open market

What came next

1. Sep 5, 2025InsiderDirector sold ~$54K of DXCM shares in the open market
2. Sep 14, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence.”
3. Oct 24, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 24, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”), pursuant to the Amended and Restated Bylaws of the Company, increased the size of the Board to ten directors and appointed Dr. Euan Ashley as a director, effective immediately.”
4. Oct 27, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Prime v. DexCom, Inc.
5. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
6. Oct 30, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 12.6%
7. Nov 10, 2025Court · District Court, S.D. New YorkSecurities lawsuit filed: Oakland County Employees Retirement System v. DexCom, Inc.
8. Nov 10, 2025Insider · 2 peopleInsiders: 2 purchases (~$1.0M), 1 sale (~$218K)
9. Nov 12, 2025InsiderDirector sold ~$59K of DXCM shares in the open market
10. Nov 14, 2025InsiderDirector sold ~$172K of DXCM shares in the open market
11. Nov 18, 2025FDAFDA device clearance: Dexcom Smart Basal
12. Nov 25, 2025Court · District Court, S.D. CaliforniaSecurities lawsuit filed: Boston Retirement System v. Dexcom, Inc.
13. Dec 17, 2025FDAFDA device clearance: Dexcom G7 Continuous Glucose Monitoring (CGM) System, Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System
14. Dec 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“As previously reported on the Current Report on Form 8-K filed on July 30, 2025, the Board of Directors (the “Board”) of DexCom, Inc. (“Dexcom” or the “Company”) appointed Jacob S. Leach, President and Chief Operating Officer, as the President and Chief Executive Officer and as a director of the Company, effective January 1, 2026, following Kevin R. Sayer’s resignation, effective as of such date.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Dexcom

For Dexcom, OQRO holds 20 insider filings (SEC Form 4 or Form 144) and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its DXCM page.

Other recent filings by Sadie Stern, EVP, Chief HR Officer

• SEC Form 4 at Dexcom (DXCM)Sep 30, 2026
• SEC Form 4 at Dexcom (DXCM)Aug 28, 2026
• SEC Form 4 at Dexcom (DXCM)Jul 29, 2025
• SEC Form 4 at Dexcom (DXCM)Jun 30, 2025
• SEC Form 4 at Dexcom (DXCM)May 28, 2025

The full history of Sadie Stern, EVP, Chief HR Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Dexcom

• SEC Form 4Sep 30, 2026
• SEC Form 144Sep 28, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 4Sep 16, 2026
• SEC Form 144Sep 15, 2026

Everything OQRO holds on this company is on its DXCM page.